Biotechgate

How are life sciences M&A deals evolving by sector? Earlier this year, we published our M&A report covering 2024. Biotechgate data reveals shifting trends in M&A deal values across biotech, #pharma, digital health and medtech. 👉 Biotech Therapeutics remains a dominant force, though its proportion has fluctuated in recent years. 👉 Pharma saw a major presence in past years but has declined in recent deal value share. 👉 #DigitalHealth had a peak in 2022 but has tapered off since. 👉 Medtech reached a high in 2017 and has had small but consistent proportions since. For more insights into the world of #lifesciences M&A activity, read our full report: https://lnkd.in/eK2zatMz

📆 #BIOEuropeSpring kicks off on Monday! The Biotechgate team will be on-site in Milan, ready to meet. If you're attending, make sure to book your one-to-one meeting via partneringONE or stop by to learn about our BD&L database. See you there!

How has the M&A landscape in the life sciences industry shifted over the past decade? 📊 Our latest report explores the highs and lows, with 2024 marking a significant downturn in deal value and volume. What’s behind these trends, and what might the future hold? Read the full analysis here: https://lnkd.in/eK2zatMz #LifeSciences #MergersAndAcquisitions #Finance

🇩🇪 Which #biotech assets are driving innovation in Germany? Our data reveals that #Oncology leads as the most active therapeutic area, with the majority of assets currently in preclinical development. Discover insights into Germany’s life science landscape in our free trend analysis report: https://lnkd.in/e5ZtDMWG We would like to thank our partners for their cooperation: BIO Deutschland e. V., BIO.NRW, bioRN Life Science Cluster and Germany Trade & Invest.

While financing hasn't repeated the highs of 2020 and 2021, biotechs have still been the focus of much attention. Read our breakdown of 2024 and how the #biotech therapeutics industry fared. https://lnkd.in/ezWYU-kV

The Biotechgate team will be attending #BIOEuropeSpring in Milan! Meet us on-site or schedule a meeting through the partneringONE platform to learn more about our BD&L database and Digital Partnering event series.

🇳🇱 What's the most popular #biotech therapeutics area in the Netherlands? Small Molecules has the greatest number of dedicated companies, followed by Immunotherapy. Explore the Dutch life sciences industry with our free country report, created in association with hollandbio. https://lnkd.in/gesdeMUf

Being one of the leading therapeutic areas within biopharma, find some of the key trends in #neurology, from clinical trials to assets and investment. https://lnkd.in/gXPMuxJP

Charting the evolution of M&A in the life sciences📈: From the 2020 peak fuelled by the pandemic to the sharp decline in 2024, our latest report takes a closer look at the M&A deals that took place in 2024 and the trends shaping the industry. 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: 📊Examining the trends over the past decade, the peak in M&A activity occurred around 2020, with total deal value reaching USD 291.46bn 📊In 2024, US companies continued to dominate M&A deal value for both target and acquiring companies, accounting for 82% and 61% of global dealmaking activity respectively 📊Cross-border M&A deals in the life sciences industry accounted for 51% of the total deal value, a significant increase from 2023 Read the full report here: https://lnkd.in/gDt7-32H #BiotechTrends #LifeSciences #InvestinBiotech

As the 19th edition of Biotechgate Digital Partnering draws to a close, we have a final session in store. Venture Valuation AG CEO Dr. Patrik Frei will be delivering a workshop on the do's, the don'ts, and the tools you need to find ideal partners and investors. Participants can register for the session through their account at DigitalPartnering.com. Don't miss this workshop!